News coverage about MannKind Corporation (NASDAQ:MNKD) has trended very positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MannKind Corporation earned a news sentiment score of 0.52 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 89 out of 100, indicating that recent media coverage is very likely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- MNKD Aug 2017 1.000 call (finance.yahoo.com)
- Top Stock Picks for the Day: MannKind Corporation (MNKD), Crown Castle International Corp. (CCI) – AllStockNews (allstocknews.com)
- Steady Stock: Mannkind Corporation (MNKD) – Post Registrar (postregistrar.com)
- How Bad Will MannKind Corporation's Q2 Results Look? (finance.yahoo.com)
- How Bad Will MannKind Corporation’s Q2 Results Look? (fool.com)
Several brokerages recently commented on MNKD. ValuEngine downgraded shares of MannKind Corporation from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. J P Morgan Chase & Co reissued an “underweight” rating on shares of MannKind Corporation in a research report on Monday, May 22nd. Piper Jaffray Companies set a $1.00 price objective on shares of MannKind Corporation and gave the company a “sell” rating in a research report on Thursday, May 11th. Finally, S&P Equity Research cut their price objective on shares of MannKind Corporation from $1.04 to $0.83 in a research report on Monday, May 8th.
Shares of MannKind Corporation (NASDAQ:MNKD) traded up 3.39% during mid-day trading on Friday, reaching $1.22. 1,371,990 shares of the company traded hands. MannKind Corporation has a 52 week low of $0.67 and a 52 week high of $5.05. The stock has a market capitalization of $123.23 million, a PE ratio of 0.86 and a beta of 3.30. The firm has a 50 day moving average of $1.37 and a 200-day moving average of $1.22.
MannKind Corporation (NASDAQ:MNKD) last announced its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.08. The business had revenue of $3 million for the quarter, compared to analyst estimates of $3.50 million. The business’s quarterly revenue was up 2900.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.06) EPS. On average, equities research analysts expect that MannKind Corporation will post ($0.96) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Very Positive Press Coverage Very Likely to Affect MannKind Corporation (NASDAQ:MNKD) Stock Price” was originally published by BBNS and is the property of of BBNS. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://baseballnewssource.com/markets/mannkind-corporation-nasdaqmnkd-earning-very-favorable-news-coverage-study-finds-updated-updated-updated/1180269.html.
About MannKind Corporation
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with our FREE daily email newsletter.